Jubilant Pharmova Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/991me9wxdm360dow9401r9fo.pdf

Key Takeaways


Generics Restructuring & Remediation

Yadav: "From here onwards, quarter-on-quarter, our EBITDA will continue to improve."

Specialty Pharmaceuticals: Radiopharma & Allergy

Bhartia: "Now the life of the children improves substantially. They can go back to school, they can go back to their cheerful if this treatment is given. So even if it lasts for 4-5 years, it is very important, the life improvement because when they go through the chemo or any other drug program, their quality of life is very low."

CDMO Sterile Injectables & API


CRDMO & Drug Discovery


Jubilant Therapeutics Pipeline

Kazmi: "Jubilant Therapeutics is now a clinical stage biotech with higher value creation opportunities driven by emerging data from first-in-human studies and additional IND filings."

Capital Allocation & Balance Sheet

Bhartia: "There is no plans as yet. But I think we'll have to see in the next couple of years how these businesses are panning out."

Guidance & Commitments

CommitmentSpecificsTimeline
Generics cost savingsAnnualized cost opportunities worth more than Rs. 100 crore to be implementedBy Q4 FY23
Generics EBITDAQuarter-on-quarter improvement driven by production ramp-up and cost transformationFrom Q3 FY23 onwards
Roorkee FDA responseCAPA submitted; FDA response expectedMid-November 2022
CDMO API marginReturn to margin levels the business used to have in past yearsFrom next quarter onwards (no quantified target)
Radiopharmacies breakevenBreak even at the network levelBy end of FY24
MIBG Phase II approvalU.S. approval for relapse/refractory indicationFY25
MIBG Phase III approvalU.S. approval for first-line indicationFY26
JBI-802 interim dataInterim clinical data readoutEarly next year (CY2023)
CapexRs. 700-750 crore primarily for CMO and Drug Discovery expansionFY23
Product development spendRs. 250-300 croreFY23

Key Metrics

MetricQ2 FY23
Consolidated revenue₹1,600 crore, vs ₹1,657 crore in Q2 FY22 and ₹1,452 crore in Q1 FY23
Consolidated reported EBITDA₹232 crore, vs ₹344 crore in Q2 FY22 and ₹204 crore in Q1 FY23
Consolidated PAT₹5 crore, vs ₹143 crore in Q2 FY22 and ₹47 crore in Q1 FY23
Consolidated normalized PAT₹62 crore, vs ₹143 crore in Q2 FY22 and ₹47 crore in Q1 FY23
EPS₹0.34 per share, vs ₹8.97 in Q2 FY22 and ₹2.96 in Q1 FY23
Normalized EPS₹3.88 per share
Specialty Pharmaceuticals revenue₹814 crore, up from ₹651 crore in Q2 FY22 and ₹722 crore in Q1 FY23
Specialty Pharmaceuticals EBITDA margin24.4%, vs 19.9% in Q2 FY22 and 16.2% in Q1 FY23
CDMO Sterile Injectable revenue₹299 crore, vs ₹409 crore in Q2 FY22 and ₹263 crore in Q1 FY23
CDMO Sterile Injectable COVID-related deals~₹22 crore, vs ~₹162 crore in Q2 FY22 and ~₹70 crore in Q1 FY23
Generics revenue₹161 crore, vs ₹333 crore in Q2 FY22 and ₹178 crore in Q1 FY23
CRDMO revenue₹320 crore, vs ₹258 crore in Q2 FY22 and ₹280 crore in Q1 FY23
CRDMO EBITDA margin21.3%, vs 26.6% in Q2 FY22 and 16.3% in Q1 FY23
Net debt (constant currency)₹2,204 crore, vs ₹1,951 crore as on June 30, 2022
Exceptional cost (foreclosure charges)₹57 crore, including ₹48 crore of bond foreclosure charges and write-off of debt origination costs
Generics cost optimization identified>₹100 crore annualized, to be implemented by Q4 FY23
Radiopharma utilization>95% in all molecules except DTPA
MIBG Phase II trial enrollment40% to 45% of ~70 patients enrolled and dosed
MIBG Phase III trial enrollment>450 of ~700 patients dosed
Refinanced debt coupon<2%, 5-year $350 million term loan replacing $200 million bonds at 6% and $150 million term loan
FY23 capex guidance₹700-750 crore, primarily for CMO expansion and Drug Discovery Services
FY23 product development expenditure guidance₹250-300 crore